High serum CRP influences myocardial miRNA profiles in ischemia-reperfusion injury of rat heart

Eun Na Kim1,2, Chong Jai Kim1,2, So Ra Kim2, Jung-A. Song3, Han Choe3, Ki-Bong Kim4, Jae-Sung Choi5, Se Jin Oh5*

1 Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, 2 Asan Laboratory of Perinatal Science, Asan Medical Center, Seoul, Republic of Korea, 3 Department of Physiology, Asan-Minnesota Institute for Innovating Transplantation, Bio-Medical Institute of Technology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, 4 Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 5 Department of Thoracic and Cardiovascular Surgery, Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea

* wpwnn@snu.ac.kr

Abstract

Objective

Prognosis of myocardial infarction tends to be worse when serum C-reactive protein (CRP) level is high. miRNAs are also known to be involved in different pathogeneses of heart diseases such as myocardial infarction. However, how CRP is involved in myocardial infarction has not been fully elucidated. We hypothesized that serum CRP changes the miRNA profile during ischemia-reperfusion injury (IRI) of the myocardium. To confirm this hypothesis, we performed global miRNA expression profiling of myocardium using IRI and CRP infusion rat model.

Methods

After ligation of the coronary artery of rat hearts, human serum CRP was intravenously injected, and reperfusion was performed (I/R+CRP group, n = 6). Control group consisted of the sham group (n = 3), IV CRP infusion group (CRP only, n = 3), and the I/R-only group (I/R only, n = 5). We evaluated 423 miRNA expression in non-ischemic areas and areas at risk (AAR) of each group using NanoString nCounter miRNA expression assay.

Results

MiR-124 was downregulated in non-ischemic myocardium in CRP-only group. In AAR, 7 miRNAs were commonly upregulated in both I/R-only and I/R+CRP groups. And additional 6 miRNAs were upregulated in the I/R+CRP group (miR-33, miR-409-3p, miR-384-3p, miR-3562, miR-101a, and miR-340-5p). Similarly, in the non-ischemic areas, 6 miRNAs were commonly upregulated in both I/R-only and I/R+CRP groups, and additional 5 miRNAs changed in the I/R+CRP group (upregulation of miR-3559-5p, miR-499, and miR-21 and downregulation of miR-500 and miR-532-3p).
Conclusion
We showed that when serum CRP level is high, IRI results in multiple miRNA profile changes not only in ischemic areas but also in non-ischemic myocardium. Our results may provide a strong basis for studying the role of CRP and miRNAs in ischemic heart disease.

Introduction
C-reactive protein (CRP) is an acute reactant protein that is rapidly released from the liver when induced by interleukin-6 in the presence of inflammation, cell injury, or infection [1, 2]. Serum CRP level increases during acute myocardial infarction and is considered a valuable prognostic marker of ischemic heart disease [3–6].

CRP is present in the blood as a pentamer, and when it encounters damaged cell membranes, pentameric CRP (pCRP) undergoes a structural change into a monomeric form and is deposited in the damaged site [7–9]. Although pCRP plays an anti-inflammatory role in the blood, monomeric CRP (mCRP) deposited in the damaged tissue activates the complement cascades, monocytes, and oxidative damage by reactive oxygen species formation, resulting in aggravation of cell damage [10–14]. Thiele et al demonstrated that mCRP had a pathogenic role in myocardial infarction [15]. Accordingly, our previous study showed that mCRP is deposited in areas at risk (AAR) of the myocardium (ischemic, but not infarcted) with ischemia-reperfusion injury in rat heart [16].

MicroRNAs (miRNAs) are small non-coding RNAs that attach to the 3’ untranslated region of target mRNAs and negatively regulate gene expression by leading to mRNA degradation or translational repression [17–20]. miRNAs are involved in cell development, proliferation, differentiation, apoptosis, metabolism, and determining the fate of cells. Therefore, changes in miRNAs are deeply associated with the pathophysiology of many diseases [21, 22]. In particular, miRNAs play an essential role in the development of various cardiovascular diseases and are used as a marker of progression and prognosis of the disease [23, 24].

However, there has been no study about the relation of two critical factors in ischemic heart disease: serum CRP and myocardial miRNAs. In the present study, we hypothesized that serum CRP would change miRNA profiles of damaged myocardium by ischemia-reperfusion injury. To prove this hypothesis, we performed myocardial miRNA expression profiling in the ischemia-reperfusion injury rat model with CRP infusion using high-throughput NanoString nCounter technology.

Materials and methods
Removal of sodium azide from human CRP
Sodium azide in commercial CRP preparations, which is obtained from human plasma (C4063; Sigma-Aldrich, Saint Louis, Missouri), was found to induce proapoptotic effects in human umbilical vein endothelial cells [25, 26]. Therefore, we carefully dialyzed out in CRP preparations in a large volume of Tris-HCL buffer.

Endotoxin assay of human CRP
We verified that commercial CRP (C4063) does not contain lipopolysaccharide (LPS). The amount of the endotoxin was determined using a quantitative test, specifically the endpoint chromogenic Limulus amebocyte lysate (LAL) test (Lonza, Basel, Switzerland). Fifty
microliters of a 1 μg/mL sample, or an endotoxin standard (2.0, 1.0, 0.5, 0.25, and 0.1 EU/mL), were dispensed into prewarmed 37˚C endotoxin-free microplate wells. In each well, 50 μL of LAL reagent was added. Wells were incubated at 37˚C for 10 minutes. After incubation, 100 μL of prewarmed chromogenic substrate solution was added to each well and incubated at 37˚C for 6 minutes. Next, 100 μL of stop reagent [25% (v/v) acetic acid] was added and analyzed at 405 nm using a spectrophotometer. After analyzing the absorbance, the units of endotoxin were calculated using the standard curve obtained from the standard solution [15]. The extrapolated endotoxin level of the CRP protein sample after the dialysis was 0.129 EU/mL. The detection limit on the low side was 0.131 EU/mL. The endotoxin level of the CRP sample was below the detection limit.

CRP pentamer report

A previous study reported that a commercially obtained source of CRP contained measurable quantities of mCRP [27]. Therefore, we confirmed that a commercially available CRP (C4063; Sigma-Aldrich) was pentameric, spontaneously modified to monomeric form, or not contaminated with mCRP. The mCRP was obtained by the treatment of dialyzed CRP with 8 M urea and 10 mM EDTA at 37˚C for 1 hour. 0.9 μg of pCRP and mCRP was loaded onto 10% glycine gel containing 1/20th of normal levels of sodium dodecyl sulfate (0.005%). The protein bands were visualized using Coomassie staining, and the identity of the CRP was confirmed using Western blotting with anti-CRP Ab (ab32412; Abcam, Cambridge, United Kingdom; 1:250 dilution), which detects both pCRP and mCRP [15, 27].

The dialyzed CRP appeared at much higher sizes than the treated CRP did, suggesting pCRP and mCRP, respectively. The dialyzed CRP did not show any bands that were monomer size. The mCRP was detected with the anti-CRP antibody (ab32412; Abcam; 1:250 dilution). The pCRP was not transferred well onto the membrane. Therefore, the dialyzed CRP was shown to be in pentameric form (Fig 1).

Animals

We constructed a myocardial ischemia-reperfusion injury model using female Sprague Dawley rats weighing between 220 g and 260 g (gestational age range, 12–14 weeks). The animals were treated in compliance with the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, Washington, DC). Animal use protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the SMG-SNU Boramae Medical Center Biomedical Research Institute (approval number: 2016–0043). Anesthesia was performed via inhalation of isoflurane (4%) for induction followed by the intraperitoneal administration of Zoletil 50 (Virbac, Carros, France; 0.12 ml) and Xylazine (Rompun 2%; Bayer Korea, Gyeonggi-do, Republic of Korea; 0.02 ml) for maintenance. The rats were intubated with cannulas (16-gauge intravenous catheter, REF 382457; BD, Sandy, Utah) and connected to ventilators (683 rodent ventilator; Harvard Apparatus, Holliston, Massachusetts). Positive-pressure ventilation using room air at a tidal volume of 2.5 ml to 3.0 ml (10 ml/kg) and 63 to 67 breaths/min was maintained to prevent atelectasis during the procedure. Left thoracotomy via the fifth intercostal space was performed, and the pericardium was opened to expose the left coronary artery.

Experimental protocols

The experimental group consisted of the sham group (n = 3), CRP-only group (n = 3), I/R-only group (n = 5), and the I/R+CRP group (n = 6). On the sham group (n = 3), we performed
left thoracotomy and pericardiotomy without manipulation of the heart. After carrying out the procedures and then waiting for 90 minutes, we euthanized the rats and then performed autopsies (Fig 2A). On the CRP-only group (n = 3), we performed left thoracotomy and pericardiotomy and infused pCRP via the femoral vein and then waited for 90 minutes without manipulation of the heart. After that, we euthanized the rats and performed autopsies (Fig 2B). On the I/R-only group (n = 5), ischemia-reperfusion injury (IRI) was induced by ligating the left anterior descending (LAD) coronary artery approximately 2 mm distal to its origin by snaring it with 6–0 nylon double sutures (buttressed with a small piece of plastic tube for 45 minutes) and reperfusion for 45 minutes. After reperfusion, the heart was quickly excised (Fig 2C). For the I/R+CRP group (n = 6), 100 μg of highly purified and dialyzed human CRP was infused via the femoral vein after the release of coronary ligation (Fig 2D).

Fig 1. Western blot of dialyzed CRP and treated CRP with urea and EDTA. The dialyzed CRP appeared at much higher sizes than the treated CRP did, suggesting pentameric CRP (pCRP) and monomeric CRP (mCRP), respectively. Western blotting showed that the mCRP was detected with the anti-CRP antibody (ab32412). pCRP, but no mCRP, was found in infused human CRP.

https://doi.org/10.1371/journal.pone.0216610.g001
Evans blue and 2,3,5-triphenyltetrazolium chloride staining to determine infarct areas, areas at risk, and non-ischemic areas

One milliliter of diluted heparin solution (2500 IU/mL) was infused via the coronary ostium while the ascending aorta was clamped. The LAD, which had been occluded for infarct production, was again occluded with a 6–0 nylon suture, and 1% Evans blue was injected to stain the perfused myocardium. The AAR and infarct (whole ischemic areas) were left unstained. Non-ischemic areas were stained deep blue.

The left ventricles were cut from the apex to the base in 4 transverse slices. For the sliced sections of the myocardium, the middle parts of the left ventricle at the same cross section were used to measure the ischemia and infarct sizes. Selected middle portions were then cut into 4 mm slices, 1 of which was incubated in TTC (Sigma Chemical) that had been dissolved in a 100 mmol/L phosphate buffer for 15 minutes. TTC stains active mitochondria pink and negatively stains infarcted areas. Therefore, the infarcted zones remained white, whereas the viable areas (non-ischemic areas and AAR) were stained deep red with TTC. After Evans blue and TTC staining, the non-ischemic areas were stained blue, AAR were stained red, and the infarct was stained white (Fig 3). The fresh tissues were dissected by color, separated, and stored at -70°C for miRNA isolation. After Evans blue and TTC staining, fresh myocardium tissues (about 2 × 2 × 2 mm³) were excised according to their color: blue (non-ischemic area),
red (AAR, ischemic but viable area), and white (infarcted area). In the sham group and the CRP-only group, only the blue myocardium was sampled because LAD ligation was not performed in them. Excised myocardium tissues were immediately snap-frozen at -70°C in order to avoid RNA degradation.

**RNA extraction and quantification**

Total RNA was isolated from fresh frozen myocardial tissues dissected from the blue (non-ischemic area), red (AAR), and white (infarcted area) zones. Frozen tissue samples were processed on ice to prevent thawing; 3 mg of tissue was added to 700 μl QIAzol Lysis Reagent (QIAGEN, CA, USA) and homogenized using taco Prep Bead Beater (Genereach, Taichung City, Taiwan). After resting the homogenate at room temperature for 5 minutes, 140 μl chloroform was added and centrifuged at 12,000 × g for 15 min at 4°C. RNA extraction was performed using the miRNeasy Mini Kit (QIAGEN) following the manufacturer’s instructions. RNA yield and purity were assessed using the DS 11 Spectrophotometer (Denovix Inc, DE, USA).

**miRNA microarray expression by NanoString nCounter platform**

NanoString rat panel expression levels of 423 different miRNAs were measured using 100 ng of miRNA and the nCounter Rat miR version 1.5 Expression Assay Kit (NanoString Technologies, Seattle, Washington). The assay incorporates 420 mature miRNAs based on miRBase version 17 and includes 6 positive mRNA controls, 8 negative mRNA controls, 3 ligation positive, 3 ligation negative synthetic miRNA controls, and 4 miRNA housekeeping controls (internal reference genes; Actb, B2m, Gapdh, and Rpl19).

Hybridizations were carried out by combining 5 ul of each RNA sample with 20 ul of nCounter Reporter probes in hybridization buffer and 5 ul of nCounter Capture probes (for a total reaction volume of 30 ul) overnight at 65°C for 16 to 20 hours. Excess probes were removed using two-step magnetic bead-based purification on the nCounter Prep Station (NanoString Technologies). Abundances of specific target molecules were quantified on the nCounter Digital Analyzer by counting the individual fluorescent barcodes and assessing the target molecules. For each assay, a high-density scan encompassing 280 fields of view was performed. The data was collected using the nCounter Digital Analyzer after taking images of the immobilized fluorescent reporters in the sample cartridge with a CCD camera.

**Data analysis**

miRNA data analysis was performed using the nSolver Analysis Software (version 3.0) freely available from NanoString Technologies. The global mean of top 100 miRNA expressers in the samples tested was used to content normalize the miRNA expression across all samples as described previously [28, 29].

Statistical analyses were performed with the R software [30]. Thirty miRNAs with average expression count > 10 were selected. Fold change > 2 was set as upregulation, and < -2 as downregulation. P values < .05 were considered statistically significant.

**Results**

We compared the expression level of 420 rat miRNAs in non-ischemic myocardium (blue area) and ischemic but viable myocardium (red area) of each group (CRP-only group, I/R-only group, and I/R+CRP group) to that of the sham group. Normalized NanoString signals data are provided in supporting information files (S1 and S2 Data). For the CRP-only group,
we infused only CRP without ischemia-reperfusion injury. Therefore, we could obtain only non-ischemic myocardium in the CRP-only group. The level of miR-124 was significantly lower in the CRP-only group than the sham group (fold change, -3.07; P = .02).

For the ischemic but viable myocardium (red myocardium), 8 miRNAs (miR-3564, miR-592, miR-3557-5p, miR-337, miR-3575, miR-501, miR-3596b, and miR-376b-3p) were upregulated, and 1 miRNA (miR-127) was downregulated in the I/R-only group. Seven miRNAs (miR-3585-5p, miR-1224, miR-3555, miR-3120, miR-1949, miR-190, and miR-448) were commonly upregulated in both the I/R-only group and the I/R+CRP group. Similar to the trend of ischemic myocardium, additional 6 miRNAs (miR-33, miR-409-3p, miR-384-3p, miR-3562, miR-101a, and miR-340-5p) were upregulated only in non-ischemic myocardium in the I/R+CRP group (Fig 4A; Table 1).

In non-ischemic myocardium (blue area), 9 miRNAs were upregulated, and 1 miRNA (miR-451) was downregulated in the I/R-only group. Six miRNAs (miR-3585-5p, miR-448, miR-1949, miR-1224, miR-190, and miR-340-5p) were commonly upregulated in both the I/R-only and I/R+CRP groups than in the sham group. However, unlike in the CRP-only and I/R-only groups, 3 miRNAs (miR-3559-5p, miR-499, and miR-21) were upregulated, and 2 miRNAs (miR-500 and miR-532-3p) were downregulated in only the I/R+CRP group (Fig 4B; Table 2).

**Discussion**

This study shows that serum CRP influences the miRNA profiles in damaged myocardium by ischemia-reperfusion injury. In our experiments, the expression levels of multiple miRNAs change in non-ischemic myocardium as well as in ischemic myocardium in response to CRP infusion.

For ischemic area, 7 miRNAs upregulated in both I/R-only and I/R+CRP group are regarded as changes induced by IRI. Six miRNAs upregulated only in I/R+CRP group (miR-33, miR-409-3p, miR-384-3p, miR-3562, miR-101a, and miR-340-5p) are considered to have

---

**Fig 4. miRNA expression profiles.** Global miRNA expression analysis of ischemic but viable myocardium (A, red myocardium by Evans blue and TTC staining) and non-ischemic myocardium (B, blue myocardium by Evans blue and TTC staining). Venn diagrams (upper) and corresponding heat maps (lower) show significantly different expressions of miRNAs when compared to sham group. miRNAs with average expression count > 10, fold change >2 or < -2, and P value < .05 were selected.

https://doi.org/10.1371/journal.pone.0216610.g004
been influenced by CRP infusion (Fig 4A; Table 1). Four of these 6 miRNAs identified only in the I/R+CRP group (miR-33, miR-409-3p, miR-384-3p and miR-101a) were found to be involved in myocardial disease. Recent studies have shown that the expression level of miR-33 is elevated in heart failure [31] and that miR-33 promotes myocardial fibrosis [32] and vascular atherosclerosis [33]. Currently, miR-33 is being considered as a new therapeutic target [34]. Consequently, our study suggests that upregulation of miR-33 may be a missing link between bad prognosis of ischemic heart disease and high serum CRP level. Interestingly, the miRNAs (miR-409-3p, miR-384-3p, and miR-101a) that were upregulated after CRP infusion in our present study have been shown to have cardioprotective roles or downregulated in patients with heart diseases: miR-409-3p was significantly downregulated in mitral regurgitation patients with heart failures in a previous case-control study [35]; miR-384-3p was downregulated in ischemic myocardium of rat and was shown to regulate apoptosis pathway to play a cardioprotective role in myocardial ischemia [36]; miR-101a was shown to mitigate cardiac fibrosis in postinfarct rats [37]; miR-340-5p was shown to inhibit cell proliferation and increase apoptosis in various types of cancer cells [38–40].

For non-ischemic myocardium, 6 miRNAs were changed in both I/R-only and I/R+CRP groups, and additional 5 miRNAs (upregulation of miR-3559-5p, miR-499, miR-21 and downregulation of miR-500 and miR-532-3p) were changed in I/R+CRP group; this is regarded as the effect of CRP infusion (Fig 4B; Table 2). Among these miRNAs, miR-499, miR-21, and miR-500 are known to be involved in heart disease. miR-499 is highly expressed in myocardocytes and increase in acute myocardial infarction [41–45]. miR-21 has an important role in cardiac fibrosis after myocardial infarction [46] and for regulating fibroblast proliferation [47]. Furthermore, miR-500 was downregulated in patients with diastolic dysfunction [48].

Functional recovery after ischemic injury depends on the amount of remaining non-ischemic myocardium and the recovery from reperfusion of the ischemic area. Many miRNAs change both in non-ischemic and ischemic myocardium when IRI occurs in high serum, and the changes may have important roles in aggravating heart conditions. The pathogenesis of dysregulation of these miRNAs and its role should be elucidated in future research.

Table 1. Genes significantly changed in each group compared to the sham group in ischemic but viable myocardium (red area by evans blue and TTC staining).

| Gene Name I/R vs Sham | Fold change | P value | Average expression count | Gene Name I/R+CRP vs Sham | Fold change | P value | Average expression count |
|------------------------|-------------|---------|-------------------------|---------------------------|-------------|---------|-------------------------|
| rno-miR-3585-5p        | 31.6        | .00484081 | 31.6                    | 1                         | rno-miR-3585-5p        | 20.96    | .00199687               | 20.96        | 1                     |
| rno-miR-1224           | 3.62        | .00659538 | 97.09                   | 26.85                     | rno-miR-1224           | 3.93     | .00052359               | 105.43       | 26.85     |
| rno-miR-3555           | 3.18        | .01800967 | 12.44                   | 3.92                      | rno-miR-3555           | 3.09     | .01780053               | 12.1          | 3.92      |
| rno-miR-3120           | 2.7         | .00485023 | 13.78                   | 5.11                      | rno-miR-3120           | 2.16     | .01399395               | 11.06         | 5.11      |
| rno-miR-1949           | 2.58        | .00168606 | 236.52                  | 91.68                     | rno-miR-1949           | 2.17     | .00439291               | 198.75        | 91.68     |
| rno-miR-190            | 2.53        | .01061211 | 49.88                   | 19.68                     | rno-miR-190            | 2.84     | .01642446               | 55.82         | 19.68     |
| rno-miR-448            | 2.49        | .02966429 | 15.06                   | 6.04                      | rno-miR-448            | 3.2      | .01399491               | 19.3          | 6.04      |
| rno-miR-3564           | 8.56        | .03530545 | 31.15                   | 3.64                      | rno-miR-33             | 4.97     | .03085913               | 10.72         | 2.16      |
| rno-miR-592            | 3.46        | .01995102 | 10.76                   | 3.11                      | rno-miR-409-3p         | 3.96     | .00059162               | 13.56         | 3.42      |
| rno-miR-3557-5p        | 2.56        | .02299442 | 15.55                   | 6.08                      | rno-miR-384-3p         | 3.82     | .01736719               | 13.06         | 3.42      |
| rno-miR-337            | 2.28        | .04114917 | 14.07                   | 6.16                      | rno-miR-3562           | 3.74     | .00213201               | 11.87         | 3.18      |
| rno-miR-3575           | 2.27        | .04284919 | 25.34                   | 11.16                     | rno-miR-101a           | 2.59     | .00068688               | 26.33         | 10.17     |
| rno-miR-501            | 2.2         | .04875308 | 63.05                   | 28.67                     | rno-miR-340-5p         | 2.03     | .04336423               | 23.46         | 11.55     |
| rno-miR-3596b          | 2.15        | .02778967 | 20.3                    | 9.44                      |                     |          |                         |               |          |
| rno-miR-376b-3p        | 2.06        | .04421247 | 10.4                    | 5.04                      |                     |          |                         |               |          |
| rno-miR-127            | -2.68       | .02952817 | 4.44                    | 11.9                      |                     |          |                         |               |          |

https://doi.org/10.1371/journal.pone.0216610.t001
miR-124 is downregulated in non-ischemic myocardium with high serum CRP level

Interestingly, miR-124 is significantly downregulated in CRP-infused myocardium even in the absence of ischemic injury. Previous studies have shown the harmful effect of miR-124 on the myocardium. miR-124 expression is known to be an adverse prognostic factor in heart failure that suppresses angiogenesis [49]. Downregulation of miR-124 is known to have a protective role in damaged myocardium, suppressing Angiotensin II–induced myocardial hypertrophy along with the attenuation of ER stress [50]. A substudy of a randomized clinical trial of 519 patients showed that miR-124-3p level was associated with neurological outcomes and lower survival rates in cardiac arrest patients [51]. Our results showed that serum CRP increased miR-124 level. We suggest that an increase in miR-124 level induced by CRP might be associated with bad prognosis of cardiovascular diseases.

Infusion of dialyzed human pentameric CRP in rat ischemia-reperfusion injury model

Whereas the serum CRP released from rat liver does not activate the complement cascade by itself, human CRP does cause the complement cascade in a rat, mimicking the effects of CRP on complement activation in humans [52, 53]. Therefore, many studies that focus on the effects of CRP on complement used human CRP instead of rat CRP. Therefore, the present study used human CRP and not rat CRP.

To obtain purified endotoxin-free, azide-free human CRP, we carefully dialyzed and removed sodium azide from commercial CRP obtained from human plasma. A previous study showed that LPS contamination in commercial CRP was responsible for cell activation events [26]. We then performed endotoxin assay to confirm the absence of LPS in the infused human CRP. We also confirmed whether the infused CRP had spontaneously changed to a monomeric form. Using these methods, we were able to conduct a sophisticated, well-controlled experiment.
Polymeric CRP and monomeric CRP

We performed immunohistochemical staining of heart sections using formalin-fixed, paraffin-embedded, 4-μm-thick tissue sections with a human monoclonal anti-CRP antibody (C1688; Sigma-Aldrich; 1:400 dilution), which specifically detects the monomeric form of CRP (mCRP). The I/R+CRP group showed diffuse and strong immunopositivity for anti-mCRP antibody in their damaged myocardium (data not shown), which is in line with our previous finding that mCRP is deposited on AAR myocardium damaged by IRI [16]. Moreover, CRP mRNA was not detected by PCR in our previous study, which supports the idea that mCRP immunopositivity is the result of mCRP deposition rather than production of CRP from the myocardium. We speculate that the deposited mCRP may carry some role in regulating the miRNA profiles in the damaged myocardium.

We showed that mCRP deposition activates complement, mitochondria destruction, autophagy production, and apoptosis in AAR myocardium and results in the increase in infarct size [16], which is consistent with the findings from a study by Yang et al. [54] mCRP deposition was limited to AAR in our previous study. In this study, miRNA profile changes occur in both AAR and non-ischemic areas after CRP injection.

Limitations of the study

We had to select and dissect 3 areas of rat heart based on the results of Evans blue and TTC staining and therefore were only able to obtain small specimens of rat heart tissue and consequently a small amount of RNA. Only NanoString apparatuses require smaller amounts of material; we could perform only the NanoString method to examine the miRNA profiles and did not validate our findings with other methods. Nevertheless, the NanoString nCounter platform is not an enzyme-dependent method, lacks RNA-amplification steps, and performs miRNA profiling with digital precision. It is therefore accurate and less error-prone [55]. Results obtained using NanoString apparatuses do not require further validation by another method [56]. The NanoString nCounter platform is being used to validate the results of another platform, RNA-Seq [57].

We did not experiment with pCRP infusion before ischemic injury, which could reflect clinical situations involving pre-existing long-standing inflammatory processes before an ischemic event such as diabetes mellitus and severe obesity. There are reports that elevated CRP level during myocardial infarction is associated with myocardial damage and consequent elevated IL-6 level rather than pre-existing inflammation.[4, 6, 58] We also intended to find changes in miRNAs in CRP-deposited damaged myocardium by injecting serum CRP after infarction.

CRP supplementation may not accurately mimic the pathological increase in serum CRP in response to myocardial infarction, because pathologically increased CRP may interact with a variety of tissues and cells. Future study should therefore utilize CRP-knockout mice in order to evaluate the role of endogenous CRP in the respective regulation of miRNA profiles in ischemic and non-ischemic myocardium.

Conclusion

We have shown that high serum CRP level with ischemia-reperfusion injury results in myocardial miRNA changes. We also showed that the miRNA changes occurred in both ischemic and non-ischemic myocardium. Many of these miRNA changes are involved in myocardial diseases. Our results may provide a strong basis for research on the relation between CRP and miRNAs and their role in ischemic heart disease and subsequent reperfusion therapy.
Supporting information

S1 Data. Normalized NanoString signals (counts) of blue myocardium.
(XLSX)

S2 Data. Normalized NanoString signals (counts) of red myocardium.
(XLSX)

Author Contributions

Conceptualization: Eun Na Kim, Chong Jai Kim, Han Choe, Se Jin Oh.

Data curation: Eun Na Kim.

Formal analysis: Eun Na Kim.

Funding acquisition: Ki-Bong Kim, Se Jin Oh.

Investigation: Eun Na Kim, So Ra Kim, Jung-A. Song, Han Choe, Jae-Sung Choi, Se Jin Oh.

Methodology: Eun Na Kim, So Ra Kim, Jung-A. Song, Han Choe, Se Jin Oh.

Project administration: Jae-Sung Choi, Se Jin Oh.

Resources: Jae-Sung Choi, Se Jin Oh.

Supervision: Chong Jai Kim, Se Jin Oh.

Validation: Se Jin Oh.

Visualization: Eun Na Kim.

Writing – original draft: Eun Na Kim.

Writing – review & editing: Chong Jai Kim, Ki-Bong Kim.

References

1. Kushner I, Feldmann G. Control of the acute phase response. Demonstration of C-reactive protein synthesis and secretion by hepatocytes during acute inflammation in the rabbit. J Exp Med. 1978; 148: 466–477. https://doi.org/10.1084/jem.148.2.466 PMID: 702046

2. Eklund CM. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem. 2009; 48: 111–136. PMID: 19803417

3. de Beer FC, Hind CR, Fox KM, Allan RM, Maseri A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J. 1982; 47: 239–243. https://doi.org/10.1136/hrt.47.3.239 PMID: 7059401

4. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol. 2006; 109: 248–256. https://doi.org/10.1016/j.ijcard.2005.06.021 PMID: 16055214

5. Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998; 31: 1460–1465. https://doi.org/10.1016/S0735-1097(98)00136-3 PMID: 9626820

6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 1997; 349: 462–466. https://doi.org/10.1016/S0140-6736(96)06791-5 PMID: 9040576

7. Kresl JJ, Potempa LA, Anderson BE. Conversion of native oligomeric to a modified monomeric form of human C-reactive protein. Int J Biochem Cell Biol. 1998; 30: 1415–1426. https://doi.org/10.1016/S1357-2725(98)00078-8 PMID: 9924810
8. Braig D, Kaiser B, Thiele JR, Bannasch H, Peter K, Stark GB, et al. A conformational change of C-reactive protein in burn wounds unmask its proinflammatory properties. Int Immunol. 2014; 26: 467–478. https://doi.org/10.1093/intimm/dxu056 PMID: 24844702

9. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woolillard KJ, Bassier N, et al. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009; 105: 128–137. https://doi.org/10.1161/CIRCRESAH.108.190611 PMID: 19520972

10. Eisenhardt SU, Habersberger J, Oliva K, Lancaster GI, Ayhan M, Woollard KJ, et al. A proteomic analysis of C-reactive protein stimulated THP-1 monocytes. Proteome Sci. 2011; 9: 1. https://doi.org/10.1186/1477-5956-9-1 PMID: 21763961

11. Telley KE, van den Berg CW. Structural and functional comparison of native pentameric, denatured monomeric and biotinylated C-reactive protein. Immunology. 2007; 120: 404–411. https://doi.org/10.1111/j.1365-2567.2006.02516.x PMID: 17163961

12. Wang HW, Sui SF. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochim Biophys Res Commun. 2001; 288: 75–79. https://doi.org/10.1006/bbrc.2001.5733 PubMed: 11594754

13. Ji SR, Wu Y, Zhu L, Potempa LA, Sheng FL, Lu W, et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). FASEB J. 2007; 21: 284–294. https://doi.org/10.1096/fj.06-6722com PMID: 17716742

14. Hatanaka K, Li XA, Masuda K, Yutani C, Yamamoto A. Immunohistochemical localization of C-reactive protein-binding sites in human atherosclerotic aortic lesions by a modified streptavidin-biotin-staining method. Pathol Int. 1995; 45: 635–641. PMID: 8548035

15. Thiele JR, Habersberger J, Braig D, Schmidt Y, Goerendt K, Maurer V, et al. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy. Circulation. 2014; 130: 35–50. https://doi.org/10.1161/CIRCULATIONAHA.113.007124 PMID: 24982116

16. Oh SJ, Na Kim E, Jai Kim C, Choi JS, Kim KB. The effect of C-reactive protein deposition on myocardium with ischaemia-reperfusion injury in rats. Interact Cardiovasc Thorac Surg. 2017; 25: 260–267. https://doi.org/10.1093/icvts/ivx107 PMID: 28475685

17. Hydbring P, Badalian-Very G. Clinical applications of microRNAs. F1000Res. 2013; 2: 136. https://doi.org/10.12688/f1000research.2-136.v3 PMID: 24627783

18. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993; 75: 855–862. https://doi.org/10.1016/0092-8674(93)90530-4 PMID: 8252622

19. Rana TM. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol. 2007; 8: 23–36. https://doi.org/10.1038/nrm2085 PMID: 17183358

20. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136: 215–233. https://doi.org/10.1016/j.cell.2009.01.002 PMID: 19167326

21. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science. 2007; 318: 1931–1934. https://doi.org/10.1126/science.1149460 PMID: 18048652

22. Gulyaeva LF, Kushlinshky NE. Regulatory mechanisms of microRNA expression. J Transl Med. 2016; 14: 143. https://doi.org/10.1186/s12967-016-0893-x PMID: 27197967

23. Sun T, Dong YH, Du W, Shi CY, Wang K, Tariq MA, et al. Role of MicroRNAs in myocardial infarction: from molecular mechanism to clinical application. Int J Mol Sci. 2017; 18. https://doi.org/10.3390/ijms18040745 PMID: 28362341

24. Islas JF, Moreno-Cuevas JE. A MicroRNA perspective on cardiovascular development and diseases: An update. Int J Mol Sci. 2018; 19. https://doi.org/10.3390/ijms19072075 PMID: 30018214

25. Liu C, Wang S, Deb A, Nath KA, Katusic ZS, McConnell JP, et al. Proapoptotic, antimigratory, antiproliferative, and antiangiogenic effects of commercial C-reactive protein on various human endothelial cell types in vitro: implications of contaminating presence of sodium azide in commercial preparation. Circ Res. 2005; 97: 135–143. https://doi.org/10.1161/01.RES.0000174612.90094.fd PMID: 15976313

26. Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol. 2005; 25: 1225–1230. https://doi.org/10.1161/01.ATV.0000164623.41250.28 PMID: 15802626

27. Slevin M, Matou-Nasri S, Turu M, Luque A, Rovira N, Badimon L, et al. Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Brain Pathol. 2010; 20: 151–165. https://doi.org/10.1111/j.1750-3639.2008.00256.x PMID: 19170684
28. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nat Rev Genet. 2012; 13: 358–369. https://doi.org/10.1038/nrg3198 PMID: 22510765

29. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Spelunker F, et al. A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol. 2009; 10: R64. https://doi.org/10.1186/gb-2009-10-6-R6 PMID: 19531210

30. Waggott D, Chu K, Yin S, Wouters BG, Liu FF, Boutros PC. NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data. Bioinformatics. 2012; 28: 1546–1548. https://doi.org/10.1093/bioinformatics/bts188 PMID: 22513995

31. Nishiga M, Horie T, Kuwabara Y, Nagao K, Baba O, Nakao T, et al. MicroRNA-33 controls adaptive fibrotic response in the remodeling heart by preserving lipid raft cholesterol. Circ Res. 2017; 120: 835–847. https://doi.org/10.1161/CIRCRESAHA.116.309528 PMID: 27920122

32. Chen Z, Ding HS, Guo X, Shen JJ, Fan D, Huang Y, et al. MiR-33 promotes myocardial fibrosis by inhibiting MMP16 and stimulating p38 MAPK signaling. Oncotarget. 2018; 9: 22047–22057. https://doi.org/10.18632/oncotarget.25173 PMID: 29774121

33. Horie T, Baba O, Kuwabara Y, Chuo Y, Watanabe S, Kinoshita M, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc. 2012; 1: e003376. https://doi.org/10.1161/JAHA.112.003376 PMID: 23316322

34. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011; 121: 2921–2931. https://doi.org/10.1172/JCI52757 PMID: 21646721

35. Chen MC, Chang TH, Chang JP, Huang HD, Ho WC, Lin YS, et al. Circulating miR-148b-3p and miR-409-3p as biomarkers for heart failure in patients with mitral regurgitation. Int J Cardiol. 2016; 222: 148–154. https://doi.org/10.1016/j.ijcard.2016.07.179 PMID: 27505319

36. Bao Y, Lin C, Ren J, Liu J. MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta (PI3K p110delta). Apoptosis. 2013; 18: 260–270. https://doi.org/10.1007/s10495-013-0802-1 PMID: 23315007

37. Pan Z, Sun X, Shan H, Wang N, Wang J, Ren J, et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation. 2012; 126: 840–850. https://doi.org/10.1161/CIRCULATIONAHA.112.094524 PMID: 22811578

38. Shi S, Chen X, Liu H, Yu K, Bao Y, Chai J, et al. LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/beta-catenin pathway. Gene. 2019; 683: 47–53. https://doi.org/10.1016/j.gene.2018.01.014 PMID: 30300682

39. Fernandez S, Risolino M, Mandia N, Talotta F, Soini Y, Incorronato M, et al. miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer. Oncogene. 2015; 34: 3240–3250. https://doi.org/10.1038/onc.2014.267 PMID: 25151966

40. Song L, Duan P, Gan Y, Li P, Zhao C, Xu J, et al. MicroRNA-340-5p modulates cisplatin resistance by targeting LPAATbeta in osteosarcoma. Braz J Med Biol Res. 2017; 50: e6359. https://doi.org/10.1590/1414-431X20176359 PMID: 28443990

41. Oerlemans MI, Mosterd A, Dekker MS, de Vrey EA, van Mil A, Pasterkamp G, et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol Med. 2012; 4: 1176–1185. https://doi.org/10.1002/emmm.201201749 PMID: 23023917

42. Creemers EE, Tijssen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012; 110: 483–495. https://doi.org/10.1161/CIRCRESAHA.111.247452 PMID: 22302755

43. Hortmann M, Walter JE, Benning L, Folio M, Mayr RM, Honegger U, et al. Droplet digital PCR of serum miR-499, miR-21 and miR-208a for the detection of functionally relevant coronary artery disease. Int J Cardiol. 2018. https://doi.org/10.1016/j.ijcard.2018.08.031 PMID: 30126654

44. Olivieri F, Antonicelli R, Lorenzi M, D’Alessandra Y, Lazzarin R, Santini G, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int J Cardiol. 2013; 167: 531–536. https://doi.org/10.1016/j.ijcard.2012.01.075 PMID: 22330002

45. Adachi T, Nakashima M, Otsuka Y, Nishimura K, Hirokawa G, Goto Y, et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin Chem. 2010; 56: 1183–1185. https://doi.org/10.1373/clinchem.2010.144121 PMID: 20395621

46. Yuan J, Chen H, Ge D, Xu Y, Xu H, Yang Y, et al. Mir-21 promotes cardiac fibrosis after myocardial infarction via targeting smad7. Cell Physiol Biochem. 2017; 42: 2207–2219. https://doi.org/10.1159/000479995 PMID: 28817807
47. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456: 980–984. https://doi.org/10.1038/nature07511 PMID: 19043405

48. Nair N, Kumar S, Gongora E, Gupta S. Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem. 2013; 376: 33–40. https://doi.org/10.1007/s11010-012-1546-x PMID: 23247724

49. Zhao Y, Yan M, Chen C, Gong W, Yin Z, Li H, et al. MiR-124 aggravates failing hearts by suppressing CD151-facilitated angiogenesis in heart. Oncotarget. 2018; 9: 14382–14396. https://doi.org/10.18632/oncotarget.24205 PMID: 29581851

50. Bao Q, Chen L, Li J, Zhao M, Wu S, Wu W, et al. Role of microRNA-124 in cardiomyocyte hypertrophy induced by angiotensin II. Cell Mol Biol (Noisy-le-grand). 2017; 63: 23–27. https://doi.org/10.14715/cmb/2017.63.4.4 PMID: 28478799

51. Devaux Y, Dankiewicz J, Salgado-Somoza A, Stammet P, Collignon O, Gilje P, et al. Association of circulating MicroRNA-124-3p levels with outcomes after out-of-hospital cardiac arrest: A substudy of a randomized clinical trial. JAMA Cardiol. 2016; 1: 305–313. https://doi.org/10.1001/jamacardio.2016.0480 PMID: 27438111

52. de Beer FC, Baltz ML, Munn EA, Feinstein A, Taylor J, Bruton C, et al. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology. 1982; 45: 55–70. PMID: 7056568

53. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006; 440: 1217–1221. https://doi.org/10.1038/nature04672 PMID: 16642000

54. Yang J, Wang J, Zhu S, Chen X, Wu H, Yang D, et al. C-reactive protein augments hypoxia-induced apoptosis through mitochondrion-dependent pathway in cardiac myocytes. Mol Cell Biochem. 2008; 310: 215–226. https://doi.org/10.1007/s11010-007-9683-3 PMID: 18165866

55. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol. 2008; 26: 317–325. https://doi.org/10.1038/nbt1385 PMID: 18278033

56. Chatterjee A, Leichter AL, Fan V, Tsai P, Purcell RV, Sullivan MJ, et al. A cross comparison of technologies for the detection of microRNAs in clinical FFPE samples of hepatoblastoma patients. Sci Rep. 2015; 5: 10438. https://doi.org/10.1038/srep10438 PMID: 26039282

57. Sabo A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, et al. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature. 2014; 511: 488–492. https://doi.org/10.1038/nature13537 PMID: 25043028

58. Sturk A, Hack CE, Aarden LA, Brouwer M, Koster RR, Sanders GT. Interleukin-6 release and the acute-phase reaction in patients with acute myocardial infarction: a pilot study. J Lab Clin Med. 1992; 119: 574–579. PMID: 1583414